Cytokine receptor zcytor17 multimers

Abstract

Novel polypeptide combinations, polynucleotides encoding the polypeptides, and related compositions and methods are disclosed for zcytor17-containing multimeric or heterodimer cytokine receptors that may be used as novel cytokine antagonists, and within methods for detecting ligands that stimulate the proliferation and/or development of hematopoietic, lymphoid and myeloid cells in vitro and in vivo. The present invention also includes methods for producing the multimeric or heterodimeric cytokine receptor, uses therefor and antibodies thereto.

1 . An isolated polynucleotide that encodes a cytokine receptor polypeptide comprising amino acid residues 33-662 of SEQ ID NO:5, wherein the cytokine receptor polypeptide forms a multimeric or heterodimeric cytokine receptor with a second cytokine receptor polypeptide comprising amino acid residues 28-979 of SEQ ID NO:7, and wherein the multimeric or heterodimeric cytokine receptor binds a ligand comprising amino acid residues 27-164 of SEQ ID NO:2.  
     
     
         2 . An expression vector comprising the following operably linked elements: 
 a transcription promoter;    a DNA segment encoding a cytokine receptor polypeptide comprising amino acid residues 33-662 of SEQ ID NO:5; and    a transcription terminator;    wherein the cytokine receptor polypeptide forms a multimeric or heterodimeric cytokine receptor with a second cytokine receptor polypeptide comprising amino acid residues 28-979 of SEQ ID NO:7, and wherein the multimeric or heterodimeric cytokine receptor binds a ligand comprising amino acid residues 27-164 of SEQ ID NO:2.    
     
     
         3 . An expression vector comprising the following operably linked elements: 
 a) a first transcription promoter; a first DNA segment encoding a first cytokine receptor polypeptide comprising amino acid residues 33-662 of SEQ ID NO:5; and a first transcription terminator; and    b) a second transcription promoter; a second DNA segment encoding a second cytokine receptor polypeptide comprising amino acid residues 28-979 of SEQ ID NO:7; and a second transcription terminator;    wherein the first cytokine receptor polypeptide and the second cytokine receptor polypeptide form a multimeric or heterodimeric cytokine receptor; and    wherein the multimeric or heterodimeric cytokine receptor binds to a ligand comprising amino acid residues 27-164 of SEQ ID NO:2.    
     
     
         4 . A cultured cell comprising the expression vector of  claim 2 , wherein the cell expresses the cytokine receptor polypeptide encoded by the DNA segment.  
     
     
         5 . A cultured cell comprising the expression vector of  claim 3 , wherein the cell expresses the first cytokine receptor polypeptide and the second cytokine receptor polypeptide encoded by the DNA segments.  
     
     
         6 . A cultured cell comprising: 
 a first expression vector comprising: 
 a) a first transcription promoter;  
 b) a first DNA segment encoding a first cytokine receptor polypeptide comprising amino acid residues 33-662 of SEQ ID NO:5; and  
 c) a first transcription terminator; and  
   a second expression vector comprising: 
 a) a second transcription promoter;  
 b) a second DNA segment encoding a second cytokine receptor polypeptide comprising amino acid residues 28-979 of SEQ ID NO:7; and  
 c) a second transcription terminator;  
   wherein the first cytokine receptor polypeptide and the second cytokine receptor polypeptide form a multimeric or heterodimeric cytokine receptor; and    wherein the multimeric or heterodimeric cytokine receptor binds to a ligand comprising amino acid residues 27-164 of SEQ ID NO:2.    
     
     
         7 . A method of producing an antibody to a soluble multimeric or heterodimeric cytokine receptor comprising a first cytokine receptor polypeptide consisting of amino acid residue 33 to amino acid residue 662 of SEQ ID NO:5 and a second cytokine receptor polypeptide consisting of amino acid residues 28-739 of SEQ ID NO:7, the method comprising: 
 inoculating an animal with the soluble multimeric or heterodimeric cytokine receptor, wherein the soluble multimeric or heterodimeric cytokine receptor elicits an immune response in the animal to produce an antibody that specifically binds the soluble multimeric or heterodimeric cytokine receptor; and    isolating the antibody from the animal.    
     
     
         8 . A method of producing a multimeric or heterodimeric cytokine receptor comprising: 
 culturing a cell according to  claim 5;  and    isolating the multimeric or heterodimeric cytokine receptor produced by the cell.    
     
     
         9 . A method of producing a multimeric or heterodimeric cytokine receptor comprising: 
 culturing a cell according to  claim 6;  and    isolating the multimeric or heterodimeric cytokine receptor produced by the cell.    
     
     
         10 . An isolated polynucleotide that encodes a soluble cytokine receptor polypeptide comprising amino acid residues 33-532 of SEQ ID NO:5, wherein the soluble cytokine receptor polypeptide forms a soluble multimeric or heterodimeric cytokine receptor with a second soluble cytokine receptor comprising amino acid residues 28-739 of SEQ ID NO:7, and wherein the soluble multimeric or heterodimeric cytokine receptor binds a ligand comprising amino acid residues 27-164 of SEQ ID NO:2.  
     
     
         11 . The isolated polynucleotide of  claim 10  wherein the soluble multimeric or heterodimeric cytokine receptor antagonizes an activity of the ligand comprising amino acid residues 27-164 of SEQ ID NO:2.  
     
     
         12 . The isolated polynucleotide of  claim 11  wherein the soluble multimeric or heterodimeric cytokine receptor inhibits proliferation of immune cells, inhibits proliferation of inflammatory cells, or inhibits an inflammatory response.  
     
     
         13 . An expression vector comprising the following operably linked elements: 
 a transcription promoter;    a DNA segment encoding a soluble cytokine receptor polypeptide comprising amino acid residues 33-532 of SEQ ID NO:5; and    a transcription terminator;    wherein the cytokine receptor polypeptide forms a soluble multimeric or heterodimeric cytokine receptor with a second soluble cytokine receptor polypeptide comprising amino acid residues 28-739 of SEQ ID NO:7, and wherein the soluble multimeric or heterodimeric cytokine receptor binds a ligand comprising amino acid residues 27-164 of SEQ ID NO:2.    
     
     
         14 . A cultured cell comprising the expression vector of  claim 13  and a second expression vector comprising: 
 a second transcription promoter;    a second DNA segment encoding a second soluble cytokine receptor polypeptide comprising amino acid residues 28-739 of SEQ ID NO:7; and    a second transcription terminator;    wherein the cell expresses the soluble cytokine receptor polypeptide encoded by the DNA segment and the second soluble cytokine receptor polypeptide encoded by the second DNA segment to form a soluble multimeric or heterodimeric cytokine receptor.    
     
     
         15 . A cultured cell comprising the expression vector of  claim 13 , wherein the cell expresses the soluble cytokine receptor polypeptide encoded by the DNA segment.  
     
     
         16 . A method of producing a soluble multimeric or heterodimeric cytokine receptor comprising: 
 culturing a cell according to  claim 15;  and    isolating the soluble multimeric or heterodimeric cytokine receptor produced by the cell.    
     
     
         17 . A composition comprising: 
 an effective amount of a soluble multimeric or heterodimeric cytokine receptor comprising a first soluble cytokine receptor polypeptide comprising amino acid residues 33-532 of SEQ ID NO:5 and a second soluble cytokine receptor comprising amino acid residues 28-739 of SEQ ID NO:7; and    a pharmaceutically acceptable vehicle.